Body Mass Index and Survival in Esophageal Adenocarcinoma Treated with Chemoradiotherapy Followed by Esophagectomy
- First Online:
- Cite this article as:
- Shridhar, R., Hayman, T., Hoffe, S.E. et al. J Gastrointest Surg (2012) 16: 1296. doi:10.1007/s11605-012-1843-4
- 249 Downloads
Body mass index (BMI) has been linked with inferior outcomes in gastrointestinal malignancies. The purpose of this study is to evaluate the effect of BMI on survival in patients with esophageal adenocarcinoma.
Medical records were analyzed for patients who underwent esophagectomy after neoadjuvant chemoradiotherapy (nCRT) for adenocarcinoma from 2000 to the present. Patients were grouped into BMI ≤25, >25–30, >30–35, and BMI >35. Overall survival (OS) and disease-free survival (DFS) were analyzed using the Kaplan–Meier method. Multivariate analysis (MVA) was performed using Cox proportional hazard regression model.
We identified 303 patients for the analysis. The only difference in patient characteristics between groups was gender. We found no difference in OS and DFS associated with BMI (p = 0.3297 for OS; p = 0.5950 for DFS). There were no differences in postoperative complications or mortality between BMI groups. MVA revealed that higher stage and less than a complete response to nCRT were prognostic for worse OS and DFS, while age, gender, type of surgery, year of diagnosis, and BMI were not prognostic.
BMI was neither associated with surgical complications nor survival in patients with esophageal adenocarcinoma treated with nCRT. BMI should not be considered a contraindication to surgical resection after nCRT.